Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-09-22
2008-12-09
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07462642
ABSTRACT:
The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
REFERENCES:
patent: 3678077 (1972-07-01), Nakanishi et al.
patent: 4602034 (1986-07-01), Briet et al.
patent: 4704355 (1987-11-01), Bernstein et al.
patent: 5126129 (1992-06-01), Wiltrout et al.
patent: 5281620 (1994-01-01), Denny et al.
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5620875 (1997-04-01), Hoffman et al.
patent: 5817684 (1998-10-01), Fleisch et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5910505 (1999-06-01), Fleisch et al.
patent: 6174873 (2001-01-01), Wrenn
patent: 6194454 (2001-02-01), Dow
patent: 6667337 (2003-12-01), Wilson
patent: 6806257 (2004-10-01), Lee et al.
patent: 2001/0041713 (2001-11-01), Waldstreicher et al.
patent: 2003/0003092 (2003-01-01), Krissansen et al.
patent: 2004/0087611 (2004-05-01), Baguley et al.
patent: 2004/0204480 (2004-10-01), Wilson et al.
patent: 2006/0009505 (2006-01-01), Baguley et al.
patent: 2007/0060637 (2007-03-01), Wilson et al.
patent: 2007/0082937 (2007-04-01), Baguley et al.
patent: 2008/0070847 (2008-03-01), Wilson et al.
patent: 2008/0070848 (2008-03-01), Wilson et al.
patent: 2008/0070849 (2008-03-01), Wilson et al.
patent: 2008/0070886 (2008-03-01), Wilson et al.
patent: 2015265 (1970-10-01), None
patent: 19721211 (1998-11-01), None
patent: 0278176 (1988-08-01), None
patent: 0326149 (1989-08-01), None
patent: 0385467 (1990-09-01), None
patent: 0488718 (1992-06-01), None
patent: 0551200 (1993-07-01), None
patent: 0743064 (1996-11-01), None
patent: 0584001 (1997-05-01), None
patent: 0121285.1 (2001-09-01), None
patent: 0206839.3 (2002-05-01), None
patent: 0225508.1 (2002-11-01), None
patent: 0604114.9 (2006-03-01), None
patent: 0157387.7 (2006-08-01), None
patent: 0517386.9 (2006-08-01), None
patent: 09040690 (1997-02-01), None
patent: 2001247459 (2001-09-01), None
patent: 336259 (1999-06-01), None
patent: 506060 (2000-07-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 94/23753 (1994-10-01), None
patent: WO 95/09621 (1995-04-01), None
patent: WO 96/32418 (1996-10-01), None
patent: WO 96/36347 (1996-11-01), None
patent: WO 97/04761 (1997-02-01), None
patent: WO 97/34482 (1997-09-01), None
patent: WO 98/25600 (1998-06-01), None
patent: WO 98/25615 (1998-06-01), None
patent: WO 98/25616 (1998-06-01), None
patent: WO 98/42332 (1998-10-01), None
patent: WO 98/42334 (1998-10-01), None
patent: WO 98/42335 (1998-10-01), None
patent: WO 98/42336 (1998-10-01), None
patent: WO 98/42337 (1998-10-01), None
patent: WO 98/42345 (1998-10-01), None
patent: WO 98/42346 (1998-10-01), None
patent: WO 98/42650 (1998-10-01), None
patent: WO 00/10600 (2000-03-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 00/48591 (2000-08-01), None
patent: WO 00/76497 (2000-12-01), None
patent: WO 01/34135 (2001-05-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34197 (2001-05-01), None
patent: WO 01/34198 (2001-05-01), None
patent: WO 02/09700 (2002-02-01), None
patent: WO03/020259 (2003-03-01), None
patent: WO 2004/039363 (2004-05-01), None
patent: WO 2005/027974 (2005-03-01), None
patent: WO 2007/023302 (2007-03-01), None
patent: WO 2007/023307 (2007-03-01), None
Rustin et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. British Journal of Cancer, 2003, vol. 88, pp. 1160-1167.
Zhao et al. Improvement of the antitumor activty of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clinical Cancer Research, 2003, vol. 9, pp. 6545-6550.
Sausville et al. Contributions of human tumor xenografts to anticancer drug development. Cancer Research, 2006, vol. 66, pp. 3351-3354.
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431.
Zhou, et al., “In Vitro and In Vivo Kinetic Interactions of the Antitumour Agent 5, 6-Dimenthylxanthenone-4-Acetic Acid with Thalidomide and Diclofenac”, Cancer Chemotherapy and Pharmacology (2001), V. 47, No. 4, pp. 319-326.
Miners, et al., “Preclinical Prediction of Factors Influencing the Elimination of 5, 6-Dimenthylxanthenone-4-Acetic Acid, a New Anticancer Drug”, Cancer Research (1997), V. 57, No. 2, pp. 284-289.
Rewcastle, et al., “Potential Antitumor Agents. 61. Structure-Activity Relationships for in Vivo Colon 38 Activity among Disubstituted 9-Oxo-9H-Xanthene-4-Acetic Acids”, Journal of Medicinal Chemistry (1991), V. 34, No. 1, pp. 217-222.
Marnett, “Aspirin and Related Nonsteroidal Anti-inflamatory Drugs as Chemopreventive Agents against Colon Cancer”, Preventive Medicine (1995), V. 24, No. 2, pp. 103-106.
The International Search Report (PCT/GB03/01320).
Zhou, et al., “Reversible Binding of the Novel Anti-Tumour Agent 5, 6-Dimethylxanthenone-4-Acetic Acid to Plasma Proteins and its Distribution into Blood Cells in Various Species”, Journal of Pharmacy and Pharmacology (2001), V. 53, pp. 463-471.
Zhou, et al., “A Difference Between the Rat and Mouse in the Pharmacokinetic Interaction of 5, 6-Dimenthylxanthenone-4-Acetic Acid with Thalidomide”, Cancer Chemother Pharmacol (2001), V. 47, pp. 541-544.
The Search Report for Application No. GB0206839.3.
Martin, Lawrence J., Ph.D., Aspirin and Related Nonsterodial Anti-inflammatory Drugs as Chemopreventive Agents against Colon Cancer, Preventive Medicine 24, 103-106 (1995).
U.S. Appl. No. 12/064,632, filed Aug. 28, 2006, Green, et al.
U.S. Appl. No. 12/064,633, filed Aug. 25, 2006, Green, et al.
Aitken, et al.; “Synthesis and Antitumour Activity of New Derivatives of Flavone-8-acetic Acid (FAA), Part 4: Variation of the Basic Structure”; Arch. Pharm. Pharm. Med. Chem.; (2000) 333(6) 181-188.
Atwell, et al.; “Potential Antitumor Agents. 60. Relationships between Structure and in Vivo Colon 38 Activity for 5-Substituted 9-Oxoxanthene-4-acetic Acids”; 1990; J. Med. Chem.; 33: 1375-1379.
Atwell, et al.; “Synthesis and anti-tumor activity of topologically-related analogues of flavoneacetic acid”; Anti-Cancer Drug Design; (1989); 4(2) 161-169.
Avastin. Http://www.centerwatch.com/patient/drugs/dru851.html, Jun. 29, 2004.
Baguley, et al.; “Immunomodulatory Actions of Xanthenone Anticancer Agents”; BioDrugs; (1997) 8(2): 119-127.
Baguley, et al.; “Mechanisms of Tumor Blood Flow Inhibition by The Antitumour Drug DMXAA (5,6-dimethylxanthenone-4-acetic acid”; Proceedings of the 11th NCI EORTC AACR Symposium; Copyright © 2000 Stichting NCI-EORTC Symposium on new drugs in cancer therapy; publ. By the AACR; Published as a Supplement to Clinical Cancer Research, vol. 6, Nov. 2000.
Baguley, et al.; “Potential of DMXAA combination therapy for solid tumors”; 2002; Expert Rev. Anticancer Ther.; 2(5): 593-603.
Baguley, et al.; “Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid”; Cancer Chemother. Pharmacol, 33(1), pp. 77-81, 1993.
Baguley, et al.; “Evidence that the 5-hydroxytryptamine antagonist, cyproheptadine, modulates nitric oxide production in mice in response to flavone acetic acid, vinblastine and other agents”; Biol. Nitric Oxide, Proc. Int. Meet.; Meeting Date 1991, vol. 2, (1992); 222-224, 1991.
Baguley, et al.; “Increased Plasma Serotonin Following Treatment With Flavone-8-Acetic Acid, 5,6-Dimethylxanthenone-4-Acetic Acid, Vinblastine, and Colchicine: Relation to Vascular Effects”; Oncology Research; (1997) 9(2), 55-60.
Barefoot, R.; “Speciation of platinum compounds: a review of re
Baguley Bruce Charles
Ching Lai-Ming
Kestell Philip
Paxton James William
Wang Liang-Chuan Steve
Anderson James D
Cancer Research Technology Limited
Foley & Lardner LLP
Marschel Ardin
LandOfFree
Anti-cancer combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cancer combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046830